专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070156342A1 Pseudo-sequence method for comparing 7tm receptors with respect to the physico-chemical properties of their binding sites 审中-公开
标题翻译：比较7tm受体相对于其结合位点的物理化学性质的伪序列方法
公开(公告)号：US20070156342A1
公开(公告)日：2007-07-05
申请号：US10547944
申请日：2004-03-05
申请人： Thomas Frimurer , Trond Ulven , Thomas Hogberg , Christian Elling
发明人： Thomas Frimurer , Trond Ulven , Thomas Hogberg , Christian Elling
IPC分类号： G06F19/00 , G06G7/48
CPC分类号： G16B20/00 , G16B15/00
摘要： A pseudo-sequence method for comparing 7TM receptors with respect to the physicochemical properties of their binding sites, the method comprising the steps of: (i) optionally, aligning part of or all of the amino acid sequence of the first 7TM receptor with part of or all or the amino acid sequence of the one or more further 7TM receptors, (ii) selecting, in a sequential or non-sequential order, at the most 12 amino acid residues per helix and/or extracellular loops, which are involved in one or more binding sites of each 7TM receptor. (iii) forming a pseudo-sequence comprising at the most 50 amino acid residues from the selected sequential or non-sequential amino acid residues, (iv) for each 7TM receptor assigning one or more physicochemical descriptors to the amino acid residues of the selected amino acid pseudo-sequence involved in one or more binding sites, (v) optionally, for each 7TM receptor mathematically manipulating the physicochemical descriptors of step (iv) to obtain a simplified measure of the physicochemical properties of the binding site. (vi) for each 7TM receptor generating a similarity score as defined herein by comparing the physicochemical descriptor or, if relevant, the simplified measure for the first 7TM receptor with the physicochemical descriptors or, if relevant, the simplified measures for the one or further 7TM receptors, (vii) optionally, ranking the 7TM receptors with respect to the physicochemical properties of their binding sites according to the similarity scores obtained in step vi)
摘要翻译：一种用于比较7TM受体相对于其结合位点的物理化学性质的伪序列方法，所述方法包括以下步骤：（i）任选地使第一7TM受体的部分或全部氨基酸序列与或全部或一个或多个其它7TM受体的氨基酸序列，（ii）以顺序或非顺序的顺序选择每个螺旋和/或细胞外环最多12个氨基酸残基，其参与一个或更多的每个7TM受体的结合位点。（iii）形成包含来自所选序列或非连续氨基酸残基的至多50个氨基酸残基的伪序列，（iv）对于每个7TM受体，将一个或多个物理化学描述符分配给所选氨基酸的氨基酸残基参与一个或多个结合位点的酸性伪序列，（v）任选地，对于每个7TM受体，在数学上操纵步骤（iv）的物理化学描述符以获得结合位点的物理化学性质的简化测量。（vi）对于每个7TM受体，通过将物理化学描述符或如果相关的第一7TM受体的简化测量与物理化学描述符相比较，或者如果相关的话，通过将一个或另外7个TM的简化测量受体，（vii）任选地，根据步骤vi）中获得的相似性得分，相对于其结合位点的物理化学性质对7TM受体进行排序，

2. 发明申请

US20060111357A1 Quinoline compounds for use in mch receptor related disorders 审中-公开
标题翻译：用于mch受体相关疾病的喹啉化合物
公开(公告)号：US20060111357A1
公开(公告)日：2006-05-25
申请号：US10538455
申请日：2003-12-11
申请人： Thomas Frimurer , Trond Ulven , Thomas Hogberg , Pia Norregaard , Paul Little , Jean-Marie Receveur
发明人： Thomas Frimurer , Trond Ulven , Thomas Hogberg , Pia Norregaard , Paul Little , Jean-Marie Receveur
IPC分类号： A61K31/519 , A61K31/517 , A61K31/498 , A61K31/4745 , A61K31/525 , A61K31/4709
CPC分类号： C07D401/04 , A61K31/435 , A61K31/4375 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/519
摘要： The present invention relates to the use of quinoline compounds for the preparation of a pharmaceutical and/or a cosmetic composition for the treatment, prophylaxis and/or diagnosis of a condition caused by or involving a melanin-concentrating hormone. The invention also relates to novel quinoline compounds per se. The quinoline compounds have been found to interact with a melanin-concentrating hormone receptor, a MCH receptor. The compounds have modulating activity on the MCH receptor such as e.g. antagonistic, agonistic or allosteric activity and are useful for medicinal or cosmetic purposes such as, e.g. in the treatment or prevention of feeding disorders like obesity, metabolic syndrome, Type II diabetes, bulimia, etc. or in the treatment or prevention of depression.
摘要翻译：本发明涉及喹啉化合物在制备药物和/或化妆品组合物中的用途，用于治疗，预防和/或诊断由黑色素浓缩激素引起或涉及的病症。本发明还涉及新的喹啉化合物本身。已发现喹啉化合物与黑色素浓缩激素受体MCH受体相互作用。这些化合物对MCH受体具有调节活性，例如。拮抗，激动或变构活性，并且可用于药物或化妆品目的，例如。治疗或预防肥胖症，代谢综合征，II型糖尿病，食欲过盛等进食障碍，或治疗或预防抑郁症。

3. 发明申请

US20060235035A1 Novel methoxybenzamibe compounds for use in mch receptor related disorders 审中-公开
公开(公告)号：US20060235035A1
公开(公告)日：2006-10-19
申请号：US10510907
申请日：2003-04-08
申请人： Thomas Hogberg , Emelie Bjurling , Jean-Marie Receveur , Trond Ulven , Paul Little , Christian Elling , Pia Norregaard
发明人： Thomas Hogberg , Emelie Bjurling , Jean-Marie Receveur , Trond Ulven , Paul Little , Christian Elling , Pia Norregaard
IPC分类号： A61K31/513 , A61K31/4747 , A61K31/4745 , A61K31/4035 , A61K31/4709 , A61K31/381 , A61K31/35 , A61K31/34
CPC分类号： C07D213/643 , C07C237/42 , C07C237/44 , C07C275/42 , C07C323/44 , C07C2601/14 , C07D207/09 , C07D207/14 , C07D211/26 , C07D211/58 , C07D213/75 , C07D233/32 , C07D295/13 , C07D317/58
摘要： Novel compounds of Formula (I) which modulate MCH activity are disclosed, in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 is a lower alkoxy group; R2 is an R1 group or hydrogen, an OH or an NH2 group, Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is selected from hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, —CHO, nitrile, alkyl, alkenyl or alkynyl groups, —SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as —CH2CF3, —CF2CF3, —CF3, —OCF3, —SCF3; —SO2NH2, —SO2NHAlk, —SO2NAlk2, —SO2Alk; X is H, F, Cl, Br, I, —SCH3, —CF3, —OCF3, —SCF3, OCH3, or lower alkyl or alkenyl group; R8 is halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, aryl groups, heteroaryl groups, heterocyclyl groups, alkylcycloalkyl groups, alkylaryl groups, alkylheterocyclyl groups, alkylheteroaryl groups, arylalkoxy groups, aryloxy groups, alkoxy groups, dialkylamino groups, —CONHAlk, —CONHAr, —CONAlk2, —NHCO-Alk, —NHCO—Ar, —CO-Alk, —CO—Ar, —SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups; or R8 is R6-Ar2—B—, in which B is a single bond or a connecting moiety; Ar2 is an Ar1 group; R6 is an R5 group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.

4. 发明申请

US20090099189A1 CRTH2 Receptor Ligands For Medicinal Uses 失效
标题翻译： CRTH2受体配体用于药用
公开(公告)号：US20090099189A1
公开(公告)日：2009-04-16
申请号：US11597873
申请日：2005-05-30
申请人： Trond Ulven , Thomas Frimurer , Oystein Rist , Evi Kostenis , Thomas Hogberg , Jean-Marie Receveur , Marie Grimstrup
发明人： Trond Ulven , Thomas Frimurer , Oystein Rist , Evi Kostenis , Thomas Hogberg , Jean-Marie Receveur , Marie Grimstrup
IPC分类号： A61K31/53 , C07D263/32 , A61K31/421 , C07D403/02 , C07D231/12 , A61K31/415
CPC分类号： A61K31/415 , A61K31/454 , C07D231/12 , C07D261/08 , C07D263/32 , C07D271/06 , C07D277/24 , C07D277/34
摘要： Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group —COON, or a carboxyl bioisostere; A1, is hydrogen or methyl; ring Ar1 is an optionally substituted phenyl ring 5- or 6-membered monocyclic heteroaryl ring, in which AA1CHO— and L2 are linked to adjacent ring atoms; rings Are2, Ar3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.
摘要翻译：式（I）化合物可用于治疗对CRTH2受体活性调节作用的疾病，例如哮喘，鼻炎，过敏性气道综合征和过敏性鼻炎支原体，其中A表示羧基-COON或羧基生物电子等排体; A1，是氢或甲基; 环Ar1是任选取代的苯环5-或6-元单环杂芳基环，其中AA1CHO-和L2与相邻的环原子连接; 环A 2，Ar 3各自独立地表示苯基或5-或6-元单环杂芳基环，或由5-或6-元碳环或杂环组成的双环系统，其被苯并稠合或稠合至5-或 6元单环杂芳基环，所述环或环系统任选被取代; t为0或1; L2和L3是如说明书中定义的连接基团。

5. 发明申请

US20090105218A1 CRTH2 Receptor Ligands For Therapeutic Use 审中-公开
标题翻译： CRTH2受体配体用于治疗用途
公开(公告)号：US20090105218A1
公开(公告)日：2009-04-23
申请号：US11597938
申请日：2005-05-30
申请人： Trond Ulven , Thomas Frimurer , Oystein Rist , Evi Kostenis , Thomas Hogberg
发明人： Trond Ulven , Thomas Frimurer , Oystein Rist , Evi Kostenis , Thomas Hogberg
IPC分类号： A61K31/196 , A61K31/44 , A61K31/381 , A61K31/341 , A61K31/5375 , A61K31/445 , A61K31/55 , A61P17/00 , A61P25/00 , A61P1/00 , A61P11/00
CPC分类号： A61K31/245 , A61K31/196 , A61K31/341 , A61K31/40 , A61K31/4453 , A61K31/5375 , A61K31/55 , A61K31/63 , A61K31/635
摘要： Compounds of formula (I) are useful in the treatment of disease responsive to modulation of CRTH2 receptor activity, wherein: A represents a carboxyl group —COOH, or a carboxyl bioisostere; L1 is a bond, —CH2—, —OCH2—, —CH2CH2— or —CH═CH—; L2 is CONH—, —NHCO—, SO2NR1—, —NR1SO2 wherein R1 is hydrogen or C1-C3 alkyl, or a divalent radical of formula (X) or (Y), wherein ring Q is a non aromatic heterocyclic ring containing 5 to 7 ring atoms, including the nitrogen shown; L3 is a divalent linker radical of formula -(Alk1)m-(Z)n-(Alk2)p as defined in the description; ring Ar1 is an optionally substituted divalent phenyl radical or divalent 5- or 6-membered monocyclic heteroaryl radical, in which L1 and the H[B]sL3L2Ar2CONH-radical are linked to adjacent ring carbon atoms; ring Ar2 is an optionally substituted 1,3-phenylene radical, or an optionally substituted divalent 5- or 6-membered monocyclic heteroaryl radical, in which AL1Ar1NHCO-radical and the H[B]sL3L2-radical are linked to ring carbon atoms which are not in ortho relationship; ring B is as defined for Ar2, or an optionally substituted cycloalkyl, N-pyrrolidinyl, N-piperidinyl or N-azepinyl ring; and s is 0 or 1.
摘要翻译：式（I）化合物可用于治疗对CRTH2受体活性调节作用的疾病，其中：A表示羧基-COOH或羧基生物电子等排体; L 1是键，-CH 2 - ， - OCH 2 - ， - CH 2 CH 2 - 或-CH-CH-; L2是CONH，-NHCO-，SO2NR1，-NR1SO2，其中R1是氢或C1-C3烷基，或式（X）或（Y）的二价基团，其中环Q是非芳族杂环， 7个环原子，包括所示的氮; L3是描述中定义的式 - （Alk1）m-（Z）n-（Alk2）p的二价连接基团; 环Ar1是任选取代的二价苯基或二价5-或6-元单环杂芳基，其中L1和H [B] sL3L2Ar2CONH-基团与相邻的环碳原子连接; 环Ar2是任选取代的1,3-亚苯基或任选取代的二价5-或6-元单环杂芳基，其中AL1Ar1NHCO-基和H [B] sL3L2-自由基与环碳原子连接，不在邻近关系; 环B如Ar 2所定义，或任选取代的环烷基，N-吡咯烷基，N-哌啶基或N-氮杂环基; s为0或1。

6. 发明申请

US20080119456A1 Substituted Thiazoleacetic Acid as Crth2 Ligands 审中-公开
标题翻译：取代噻唑乙酸作为Crth2配体
公开(公告)号：US20080119456A1
公开(公告)日：2008-05-22
申请号：US11597839
申请日：2005-05-30
申请人： Trond Ulven , Thomas Frimurer , Oystein Rist , Evi Kostenis , Thomas Hogberg , Jean-Marie Receveur , Marie Grimstrup
发明人： Trond Ulven , Thomas Frimurer , Oystein Rist , Evi Kostenis , Thomas Hogberg , Jean-Marie Receveur , Marie Grimstrup
IPC分类号： A61K31/53 , A61K31/506 , A61K31/55 , C07D417/02 , C07D413/02 , C07D403/02
CPC分类号： C07D277/30 , C07D417/04 , C07D417/06
摘要： Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis; wherein X1 is —S—, —O—, —N═N—. —NR7—, —CR7═CR8—, —CR7═N—, wherein R7 and R8 are independently hydrogen or C1-C3 alkyl; A is a carboxyl group —COOH, or a carboxyl bioisostere; rings Ar2 and Ar3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; ring B is as defined for Ar2 and Ar3, or an optionally substituted N-pyrrolidinyl, N-piperidinyl or N-azepinyl ring; s is 0 or 1; L1, L2 and L4 are linker radicals as defined in the description; Q1 and Q2 represent substituents as defined in the description.
摘要翻译：式（I）化合物可用于治疗对CRTH2受体活性调节作用的疾病，例如哮喘，鼻炎，过敏性气道综合征和过敏性鼻炎支原体炎; 其中X 1是-S - ， - O - ， - N-N-。 -NR 7 - ，-CR 7 -CR 8 - ，-CR 7-N-，其中R R 7和R 8独立地是氢或C 1 -C 3烷基; A是羧基-COOH或羧基生物电子等排体; 环Ar 2和Ar 3各自独立地表示苯基或5或6元单环杂芳基环，或由5-或6-元环组成的双环系统苯并稠合或稠合到5-或6-元单环杂芳基环的碳环或杂环，所述环或环系统任选被取代; 环B如Ar 2和Ar 3所定义，或任选取代的N-吡咯烷基，N-哌啶基或N-氮杂环丁基环; s为0或1; L1，L2和L4是描述中定义的连接基团; Q 1和Q 2表示如说明书中定义的取代基。

7. 发明申请

US20110269763A1 CRTH2 receptor ligands for medicinal uses 审中-公开
标题翻译：用于药用的CRTH2受体配体
公开(公告)号：US20110269763A1
公开(公告)日：2011-11-03
申请号：US13151317
申请日：2011-06-02
申请人： Trond Ulven , Thomas Frimurer , Øystein Rist , Evi Kostenis , Thomas Högberg , Jean-Marie Receveur , Marie Grimstrup
发明人： Trond Ulven , Thomas Frimurer , Øystein Rist , Evi Kostenis , Thomas Högberg , Jean-Marie Receveur , Marie Grimstrup
IPC分类号： A61K31/415 , A61K31/4439 , A61K31/421 , A61K31/426 , A61K31/4152 , A61K31/47 , A61K31/53 , A61K31/4196 , A61P29/00 , A61P37/00 , A61P11/00 , A61P37/08 , A61P11/06 , A61P11/08 , A61P11/02 , A61P3/00 , A61P27/02 , A61P17/00 , A61P25/28 , A61P25/14 , A61P25/06 , A61P19/04 , A61P1/04 , A61P1/00 , A61P19/02 , A61P17/06 , A61P19/06 , A61P9/10 , A61P3/10 , A61P13/12 , A61P37/06 , A61K31/41
CPC分类号： A61K31/415 , A61K31/454 , C07D231/12 , C07D261/08 , C07D263/32 , C07D271/06 , C07D277/24 , C07D277/34
摘要： Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis: wherein A represents a carboxyl group —COOH, or a carboxyl bioisostere; A1 is hydrogen or methyl; ring Ar1 is an optionally substituted phenyl ring or 5- or 6-membered monocyclic heteroaryl ring, in which AA1CHO— and L2 are linked to adjacent ring atoms; rings Ar2, Ar3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.
摘要翻译：式（I）化合物可用于治疗对CRTH2受体活性调节作用的疾病，如哮喘，鼻炎，过敏性气道综合征和过敏性鼻炎支气管炎：其中A表示羧基-COOH或羧基生物电子等排体; A1是氢或甲基; 环Ar1是任选取代的苯环或5-或6-元单环杂芳基环，其中AA1CHO-和L2与相邻的环原子连接; 环Ar2，Ar3各自独立地表示苯基或5-或6-元单环杂芳基环，或由5-或6-元碳环或杂环组成的双环系统，其被苯并稠合或稠合至5-或6-元碳环或杂环 6元单环杂芳基环，所述环或环系统任选被取代; t为0或1; L2和L3是如说明书中定义的连接基团。

8. 发明授权

US08022063B2 CRTH2 receptor ligands for medicinal uses 失效
标题翻译：用于药用的CRTH2受体配体
公开(公告)号：US08022063B2
公开(公告)日：2011-09-20
申请号：US11597873
申请日：2005-05-30
申请人： Trond Ulven , Thomas Frimurer , Øystein Rist , Evi Kostenis , Thomas Högberg , Jean-Marie Receveur , Marie Grimstrup
发明人： Trond Ulven , Thomas Frimurer , Øystein Rist , Evi Kostenis , Thomas Högberg , Jean-Marie Receveur , Marie Grimstrup
IPC分类号： A01N43/00 , C07D231/00
CPC分类号： A61K31/415 , A61K31/454 , C07D231/12 , C07D261/08 , C07D263/32 , C07D271/06 , C07D277/24 , C07D277/34
摘要： Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group —COON, or a carboxyl bioisostere; A1, is hydrogen or methyl; ring Ar1 is an optionally substituted phenyl ring 5- or 6-membered monocyclic heteroaryl ring, in which AA1CHO— and L2 are linked to adjacent ring atoms; rings Are2, Ar3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.
摘要翻译：式（I）化合物可用于治疗对CRTH2受体活性调节作用的疾病，例如哮喘，鼻炎，过敏性气道综合征和过敏性鼻炎支原体，其中A表示羧基-COON或羧基生物电子等排体; A1，是氢或甲基; 环Ar1是任选取代的苯环5-或6-元单环杂芳基环，其中AA1CHO-和L2与相邻的环原子连接; 环A 2，Ar 3各自独立地表示苯基或5-或6-元单环杂芳基环，或由5-或6-元碳环或杂环组成的双环系统，其被苯并稠合或稠合至5-或 6元单环杂芳基环，所述环或环系统任选被取代; t为0或1; L2和L3是如说明书中定义的连接基团。

9. 发明授权

US09499467B2 Ortho-fluoro substituted compounds for the treatment of metabolic diseases 有权
标题翻译：用于治疗代谢性疾病的正氟取代的化合物
公开(公告)号：US09499467B2
公开(公告)日：2016-11-22
申请号：US14110531
申请日：2012-04-03
申请人： Trond Ulven , Elisabeth Christiansen
发明人： Trond Ulven , Elisabeth Christiansen
IPC分类号： C07C57/60 , C07C255/57 , C07C317/44 , C07C51/353 , C07C51/367 , C07C253/30 , C07C315/04 , C07C255/41 , C07C59/56
CPC分类号： C07C57/60 , C07C51/353 , C07C51/367 , C07C59/56 , C07C253/30 , C07C255/41 , C07C255/57 , C07C315/04 , C07C317/44
摘要： There is provided novel fluoro-substituted compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type II diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.
摘要翻译：提供能够调节G蛋白偶联受体GPR40的新型氟取代的化合物，包含该化合物的组合物及其用于控制体内胰岛素水平和用于治疗诸如II型糖尿病，高血压，酮症酸中毒，肥胖症，葡萄糖不耐受和高血胆固醇血症和与异常高或低血浆脂蛋白，甘油三酯或葡萄糖水平相关的相关疾病。

10. 发明申请

US20110152315A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES 有权
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：US20110152315A1
公开(公告)日：2011-06-23
申请号：US13056484
申请日：2009-07-23
申请人： Trond Ulven , Elisabeth Christiansen
发明人： Trond Ulven , Elisabeth Christiansen
IPC分类号： A61K31/47 , A61K31/4418 , A61K31/4192 , A61K31/426 , A61K31/381 , A61K31/255 , A61K31/275 , A61K31/216 , A61K31/192 , C07D215/14 , C07D213/76 , C07D213/55 , C07D277/30 , C07D249/04 , C07D333/24 , C07C309/77 , C07C255/41 , C07C69/732 , C07C69/736 , C07C69/73 , C07C59/48 , C07C57/60 , A61P3/00 , A61P9/00 , A61P13/12 , A61P35/00 , A61P15/10
CPC分类号： C07D213/55 , C07C57/60 , C07C59/48 , C07C59/52 , C07C59/64 , C07C59/68 , C07C59/70 , C07C59/76 , C07C59/84 , C07C59/86 , C07C59/92 , C07C61/39 , C07C67/307 , C07C67/31 , C07C67/317 , C07C67/343 , C07C205/56 , C07C229/44 , C07C255/41 , C07C309/73 , C07C2601/02 , C07C2602/08 , C07D213/61 , C07D215/18 , C07D253/04 , C07D277/30 , C07D333/24 , C07C69/753 , C07C69/712 , C07C69/618 , C07C69/65 , C07C69/738 , C07C69/734 , C07C69/732
摘要： There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type I1 diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.
摘要翻译：提供能够调节G蛋白偶联受体GPR40的新型化合物，包含该化合物的组合物及其用于控制体内胰岛素水平和用于治疗诸如II型糖尿病，高血压，酮症酸中毒，肥胖症，葡萄糖不耐受，以及与异常高或低血浆脂蛋白，甘油三酯或葡萄糖水平相关的高胆固醇血症和相关疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式